Various preclinical and a limited number of clinical studies of CAR-NK cells have shown promising results: efficient elimination of target cells without side effects similar to CAR-T therapy. However, the homing and infiltration abilities of CAR-NK cells are poor due to the inhibitory tumor microenvironment. From the perspective of clinical treatment strategies, combined with the biological and tumor microenvironment characteristics of NK cells, CAR-NK combination therapy strategies with anti-PD-1/PD-L1, radiotherapy and chemotherapy, kinase inhibitors, proteasome inhibitors, STING agonist, oncolytic virus, photothermal therapy, can greatly promote the proliferation, migration and cytotoxicity of the NK cells. In this review, we will summarize the targets selection, structure constructions and combinational therapies of CAR-NK cells for tumors to provide feasible combination strategies for overcoming the inhibitory tumor microenvironment and improving the efficacy of CAR-NK cells.
21 April 2025 in Journal of Magnetic Resonance Imaging
Background: Changes in bone mineral density (BMD) are recognized as an independent predictor of survival in a variety of diseases. However, the prognostic value of BMD in small cell lung cancer (SCLC) patients treated with immune checkpoint inhibitors (ICIs) is not well understood. This study aimed to explore the prognostic ability of change in bone mineral density (ΔBMD) on the survival of SCLC patients receiving ICIs. Methods: A total of 300 SCLC patients receiving ICIs from three hospitals were enrolled and underwent non-enhanced thoracic computed tomography (CT) before and after treatment. Overall survival (OS) and progression-free survival (PFS) were analyzed using Cox regression models and Kaplan-Meier survival curves. A nomogram model based on independent prognostic factors was developed using multivariate Cox proportional hazards analysis. The predictive efficacy and clinical benefit of the nomogram were evaluated using the time-dependent area under the receiver operating characteristic (ROC) curve and calibration curves. Results: Lower ΔBMD was associated with shorter PFS and OS. ΔBMD was identified as an independent prognostic factor affecting OS (risk ratios =0.461; P<0.001). The established nomogram resulted in the area under the ROC curve for OS at 9, 12, and 18 months of 0.743, 0.782, and 0.781, respectively. The C-index was 0.701 [95% confidence interval (CI): 0.663–0.739], and the calibration curves confirmed that predictions aligned well with actual observations. Conclusions: Lower ΔBMD is correlated with poorer clinical outcomes in SCLC patients undergoing treatment with ICIs.
Brain metastases (BM) are the most prevalent intracranial malignancies. Approximately 30–40% of cancer patients develop BM at some stage of their illness, presenting with a high incidence and poor prognosis. Our clinical findings indicate a significant disparity in the efficacy between non-enhanced and enhanced lung cancer BM. Therefore, the aim of this study is to conduct a longitudinal MRI evaluation of the therapeutic effect of non-enhanced lung cancer BM, thereby enabling improved efficacy prediction and more personalized treatment plans. We conducted a retrospective analysis of clinical and imaging data from 72 patients with lung cancer BM. Exclusion criteria included participants with a history of primary brain tumors, other malignancies, or neurological symptoms. We performed a longitudinal MRI evaluation of 8 patients with non-enhanced BM who met the eligibility criteria. The response to systemic therapy was locally assessed using the Neuro-Oncology response assessment criteria (RANO 2.0). A total of 8 patients were included in this study, comprising 4 cases of non-enhanced BM and 4 cases featuring both enhanced and non-enhanced BM. The median follow-up time for non-enhanced BM was 19 months, with a disease control rate of 50%. In contrast, the median progression-free follow-up time for enhanced BM was 35.5 months, yielding a disease control rate of 100%. After standardized treatment in accordance with clinical guidelines, patients with enhanced BM exhibited significantly better therapeutic outcomes than those with non-enhanced BM. Cases 1–4 demonstrated non-enhanced or mildly circular-enhanced lung cancer BM, with the sizes of all 4 lesions increasing by over 60% within approximately one year, indicating disease progression. In cases 5–8, each patient presented with two lesions: enhanced (Foci 1) and non-enhanced (Foci 2) BM. Comparative analysis of Foci 1 and Foci 2 revealed significantly weaker treatment responses in non-enhanced lesions (Patients 7–8), with Patient 5 exhibiting disease progression without any response. This study demonstrates that, following standardized treatment protocols aligned with clinical guidelines, the therapeutic effect of non-enhanced lung cancer BM is inferior to that of enhanced BM. Evaluating the enhancement type of lung cancer BM is essential for efficacy prediction and holds important implications for treatment guidance.
Charcot arthropathy is a rare disease in clinic, which is easy to be misdiagnosed and delayed diagnosis. Imaging examination plays a key role in the diagnosis of Charcot arthropathy. It is important to improve the early diagnosis rate and strive for early treatment to improve the quality of life of these patients. Here we reported a rare case of charcot knee (CK) accompanied by tethered cord syndrome and lumbosacral fur sinus, who presented with joint destruction, joint deformity and multiple free bodies and received joint free bodies removal and joint replacement surgery with acceptable short and midterm follow-up results.
Background: Small cell lung cancer (SCLC) is an aggressive malignancy with heterogeneous survival outcomes. Conventional staging systems do not fully capture the influence of multimodal treatment strategies or molecular pathological characteristics on prognosis. However, prognostic models integrating treatment modalities with molecular pathology remain limited in SCLC. This study aimed to evaluate the survival impact of multimodal treatments and develop a nomogram incorporating clinical and molecular features for individualized prognostic prediction. Methods: This retrospective multicenter study included patients diagnosed with SCLC between 2020 and 2024 at three medical centers. Patients from two centers were randomly divided into a derivation cohort (70%) and an internal validation cohort (30%), while patients from the third center served as an independent external validation cohort. Overall survival (OS) was the primary endpoint. Candidate predictors were selected using the Boruta algorithm and the least absolute shrinkage and selection operator (LASSO) regression, and a multivariable Cox proportional hazards model was used to construct a nomogram for predicting 1-year OS. Model performance was evaluated using time-dependent receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA), and was further compared with the tumor, node, metastasis (TNM) staging system and Veterans Administration Lung Study Group (VALG) staging system. Results: A total of 728 patients were included and assigned to the derivation cohort (n=468), internal validation cohort (n=200), and external validation cohort (n=60). A nomogram incorporating pathological score, therapy, clinical T stage, clinical N stage, and TNM clinical stage was developed. The nomogram showed better discrimination than the TNM and VALG staging systems in the derivation cohort, with an area under the ROC curve (AUC) of 0.801 and a 95% confidence interval (CI) of 0.758–0.844, versus 0.664 (95% CI: 0.609–0.719) and 0.603 (95% CI: 0.051–0.655), respectively; similar results were observed in the internal validation cohort [0.800 (95% CI: 0.734–0.866) vs. 0.649 (95% CI: 0.560–0.738) and 0.569 (95% CI: 0.488–0.650)] and the external validation cohort [0.776 (95% CI: 0.646–0.906) vs. 0.611 (95% CI: 0.460–0.762) and 0.593 (95% CI: 0.462–0.725)]. Calibration curves showed good agreement between predicted and observed 1-year OS, and DCA demonstrated favorable clinical utility across all cohorts. Conclusions: Multimodal treatment strategies were associated with survival in advanced SCLC. The proposed nomogram improved individualized 1-year survival prediction beyond conventional staging systems in SCLC. By integrating treatment-related and pathological information with clinical staging variables, this approach may support risk stratification, treatment intensity, and inform follow-up planning in clinical practice.